On March 10, 2026, Aspargo Labs submitted an application to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) seeking to reclassify its patented liquid oral sildenafil suspension from Prescription Only Medicine (POM) to Pharmacy (P) medicine status. If approved, the product — currently marketed in the UK as HEZKUE — would be available over the counter under pharmacist supervision, no prescription required.

Why It Matters

The UK already allows OTC sildenafil (Viagra Connect launched as a pharmacy medicine in 2018), so the regulatory pathway exists. But a liquid spray format represents a meaningful innovation in an increasingly competitive OTC ED market. If approved, Aspargo's product would offer a differentiated delivery mechanism — faster onset, no water needed, easier for patients who struggle with pills. Combined with VYBRIQUE's oral film in the US, the trend is clear: the next generation of ED treatments is moving beyond the blue pill toward formats designed for convenience, speed, and discretion. The telehealth platforms (Hims, Ro, BlueChew) will be watching closely.

The technology replaces traditional ED pills with a spray delivered directly into the mouth, where specially engineered nanoparticles protect the active ingredient from breakdown while enhancing solubility for faster absorption through oral tissue. Chief Medical Officer Dr. Steve Kaplan said the approach is "designed to make medications work faster and be easier to take as prescribed — improving both adherence and the overall patient experience."

The MHRA submission includes a smaller pack size and proprietary formulation data tailored to the pharmacy channel. No specific approval timeline has been provided. The filing follows VYBRIQUE's February 2026 FDA approval in the US as the first sildenafil oral dissolving film — suggesting a broader industry shift toward non-pill ED formats that prioritize convenience and discretion.

Sources

Update — 2026-03-23

Initial entry — story first created.